Back to top
more

Exact Sciences (EXAS)

(Delayed Data from NSDQ)

$59.70 USD

59.70
1,690,395

+0.64 (1.08%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $59.70 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

John Blank headshot

What Role Will Macro Data Play, Before the U.S. Election?

In other words, can U.S. macro data trump any U.S election uncertainty?

Does Exact Sciences (EXAS) Have the Potential to Rally 34.13% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 34.1% in Exact Sciences (EXAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches

Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard through screening programs.

Exact Sciences (EXAS) Enrolls First Patient in Pivotal MCED Study

Exact Sciences (EXAS) initiates the MCED Falcon Registry study, with Baylor Scott & White Health and Endeavor Health serving as the primary study sites.

Why You Should Add Exact Sciences (EXAS) to Your Portfolio

Exact Sciences' (EXAS) progress with strategic priority and strong solvency bode well.

The Zacks Analyst Blog Highlights Nomura Research Institute, Manhattan Associates and Exact Sciences

Nomura Research Institute, Manhattan Associates and Exact Sciences are part of the Zacks top Analyst Blog.

John Blank headshot

Volatility Stays with Markets: Global Week Ahead

Investors should have learned by now that there's no such thing as a "quiet" summer in the markets. A year ago, bond yields rose sharply on worries about the U.S. fiscal outlook. The summer before, inflation and rate hike fears jolted markets.

Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top

Nektar (NKTR) reports a wider-than-expected loss in the second quarter of 2024 while revenues beat estimates. Stock falls in after-hours trading.

Ironwood (IRWD) Q2 Earnings & Revenues Fall Shy of Estimates

Ironwood (IRWD) reports breakeven earnings for second-quarter 2024. Revenues miss estimates. The company lowers revenue guidance for 2024. Stock falls.

Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top

Mirum's (MIRM) earnings miss estimates in the second quarter of 2024 while revenues beat the same. Livmarli drives year-over-year sales.

SpringWorks (SWTX) Q2 Earnings Beat, Ogsiveo Drives Revenues

SpringWorks (SWTX) reports better-than-expected second-quarter results. The newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.

Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss

Beam Therapeutics (BEAM) reports mixed second-quarter results. The company remains focused on pipeline development.

Halozyme's (HALO) Q2 Earnings & Sales Top Estimates, Stock Up

Halozyme (HALO) reports better-than-expected second-quarter 2024 results. The company maintains revenue guidance for 2024. Stock rises in after-hours trading.

Looking for Medical Stocks? The Zacks Rank Can Help You Find Winners

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.

Wall Street Analysts Predict a 45.04% Upside in Exact Sciences (EXAS): Here's What You Should Know

The consensus price target hints at a 45% upside potential for Exact Sciences (EXAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Exact Sciences (EXAS) Q2 Loss Narrower Than Expected, Sales Beat

Exact Sciences' (EXAS) second-quarter 2024 top-line results reflect robust revenues from the Screening and Precision Oncology segments.

Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates

Exact Sciences (EXAS) delivered earnings and revenue surprises of 75.68% and 1.55%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?

Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

Why Is Exact Sciences (EXAS) Down 17.5% Since Last Earnings Report?

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

Exact Sciences (EXAS) Witnesses Rising Expenses, Competition

Exact Sciences (EXAS) has numerous competitors, given the large market for colorectal cancer screening.

Exact Sciences (EXAS) to Showcase Favorable Research Outcome

Exact Sciences' (EXAS) latest study research result shows commitment to innovation and strategies that expand access to effective cancer screening and diagnostic tools for patients.

Is Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) a Strong ETF Right Now?

Smart Beta ETF report for PRFZ